New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
11:58 EDTALNYAlnylam updates increase confidence in upcoming data, says Piper Jaffray
After Alnylam presented new data on its Phase II study of patisiran in patients with Familial Amyloidotic Polyneuropathy, PiperJaffray says that the data increases its optimism about the outlook for a Phase III trial of the treatment in 2016. The firm keeps an Overweight rating on the stock.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
08:36 EDTALNYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:03 EDTALNYAlnylam completes enrollment in APOLLO Phase 3 study with Patisiran
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use